Health Care Innovation
Drug Innovation
PRI Warns Proposed COINS Act Rule Could Undermine America’s Medical Innovation Leadership
Yesterday, the Treasury Department issued a proposed rule implementing the Comprehensive Outbound Investment National Security (COINS) Act, which restricts certain U.S. investments in China and other countries of concern. The proposal would expand existing outbound investment restrictions to include biotechnology. Sally C. Pipes, President and CEO of the Pacific Research ...
Commentary
Peptide Dangers Result in Hospitalizations
The peptide market has raced far ahead of both the science and the safeguards meant to protect patients. Federal regulators need to take the explosion of unapproved injectable peptides far more seriously — and target the sellers and suppliers fueling it. Peptide use has grown well beyond a handful of ...
Commentary
The FDA Is Struggling To Police The Peptide Boom
Unlike FDA-approved peptide medicines, many compounds marketed online have never undergone rigorous clinical testing or regulatory review. That leaves fundamental questions about their safety and effectiveness unanswered. The bigger challenge is the supply chain. Overseas manufacturers can profit from American demand while making it difficult for U.S. authorities to enforce ...
Commentary
The $3.3 Trillion Case For Bayh-Dole
The federal government once held roughly 28,000 patents on inventions arising from taxpayer-supported research. Almost none of them went anywhere. By 1980, the government had managed to license fewer than 5% of them. Then Congress changed the rules. The Bayh-Dole Act of 1980 allowed universities, nonprofits, and small businesses to ...
Commentary
Consumer Choice Should Apply to Hospitals as Well
Americans are clamoring for relief from soaring healthcare prices. Thankfully, Congress seems to be looking in the right place for the answer. Last week, members of a House Judiciary subcommittee heard testimony on “the effect of mergers, certificate of need laws, regulations, vertical integration, and fraudulent insurance practices on healthcare ...
Commentary
The first mRNA flu vaccine may be just the beginning
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it. Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard ...
Commentary
GOP Shouldn’t Run Away from Healthcare Reform
The Midterms Loom, Republicans Would Be Wise to Run on Healthcare Reform Ever since the congressional GOP failed to repeal Obamacare and then lost the 2018 midterms, Republicans have shied away from running on market-based healthcare reform. But that’s the wrong strategy, according to President Trump’s chief pollster Tony Fabrizio ...
Biosimilars
Biosimilars offer NC rare opportunity to save millions without cutting care
As healthcare costs continue to rise, North Carolina lawmakers face a difficult and increasingly ongoing challenge: how to preserve quality health coverage for more than 750,000 teachers, state employees, retirees and their families without asking taxpayers to spend more or patients to pay higher premiums and out-of-pocket costs . . ...
Drug Innovation
California Supreme Court Decision Protects Future Medical Innovation
The Pacific Research Institute – the non-partisan, California-based, free-market think tank – today hailed a landmark California Supreme Court decision protecting future medical innovation. The ruling in the Gilead Tenofir Cases overturns a lower court decision that threatened to expose pharmaceutical innovators to sweeping new liability for decisions about the ...
Commentary
Hospital price transparency is good politics — and good policy
Few issues will shape this November’s midterm elections more than the rising cost of healthcare. Republicans returning home for the August recess can point to meaningful progress on one of the biggest drivers of those costs: hospital prices. In recent weeks, Congress has moved closer to making hospital price transparency ...
PRI Warns Proposed COINS Act Rule Could Undermine America’s Medical Innovation Leadership
Yesterday, the Treasury Department issued a proposed rule implementing the Comprehensive Outbound Investment National Security (COINS) Act, which restricts certain U.S. investments in China and other countries of concern. The proposal would expand existing outbound investment restrictions to include biotechnology. Sally C. Pipes, President and CEO of the Pacific Research ...
Peptide Dangers Result in Hospitalizations
The peptide market has raced far ahead of both the science and the safeguards meant to protect patients. Federal regulators need to take the explosion of unapproved injectable peptides far more seriously — and target the sellers and suppliers fueling it. Peptide use has grown well beyond a handful of ...
The FDA Is Struggling To Police The Peptide Boom
Unlike FDA-approved peptide medicines, many compounds marketed online have never undergone rigorous clinical testing or regulatory review. That leaves fundamental questions about their safety and effectiveness unanswered. The bigger challenge is the supply chain. Overseas manufacturers can profit from American demand while making it difficult for U.S. authorities to enforce ...
The $3.3 Trillion Case For Bayh-Dole
The federal government once held roughly 28,000 patents on inventions arising from taxpayer-supported research. Almost none of them went anywhere. By 1980, the government had managed to license fewer than 5% of them. Then Congress changed the rules. The Bayh-Dole Act of 1980 allowed universities, nonprofits, and small businesses to ...
Consumer Choice Should Apply to Hospitals as Well
Americans are clamoring for relief from soaring healthcare prices. Thankfully, Congress seems to be looking in the right place for the answer. Last week, members of a House Judiciary subcommittee heard testimony on “the effect of mergers, certificate of need laws, regulations, vertical integration, and fraudulent insurance practices on healthcare ...
The first mRNA flu vaccine may be just the beginning
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it. Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard ...
GOP Shouldn’t Run Away from Healthcare Reform
The Midterms Loom, Republicans Would Be Wise to Run on Healthcare Reform Ever since the congressional GOP failed to repeal Obamacare and then lost the 2018 midterms, Republicans have shied away from running on market-based healthcare reform. But that’s the wrong strategy, according to President Trump’s chief pollster Tony Fabrizio ...
Biosimilars offer NC rare opportunity to save millions without cutting care
As healthcare costs continue to rise, North Carolina lawmakers face a difficult and increasingly ongoing challenge: how to preserve quality health coverage for more than 750,000 teachers, state employees, retirees and their families without asking taxpayers to spend more or patients to pay higher premiums and out-of-pocket costs . . ...
California Supreme Court Decision Protects Future Medical Innovation
The Pacific Research Institute – the non-partisan, California-based, free-market think tank – today hailed a landmark California Supreme Court decision protecting future medical innovation. The ruling in the Gilead Tenofir Cases overturns a lower court decision that threatened to expose pharmaceutical innovators to sweeping new liability for decisions about the ...
Hospital price transparency is good politics — and good policy
Few issues will shape this November’s midterm elections more than the rising cost of healthcare. Republicans returning home for the August recess can point to meaningful progress on one of the biggest drivers of those costs: hospital prices. In recent weeks, Congress has moved closer to making hospital price transparency ...